Does Selexipag Interact with Gemfibrozil?
CDI records a contraindicated classification for Selexipag and Gemfibrozil. The stored summary is: Strong CYP2C8 inhibitor that doubled selexipag exposure and increased active metabolite exposure approximately 11-fold. Concomitant use is contraindicated. The mechanism involves cyp2c8 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
Evidence status
A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.
Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.
Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.
- Stored CDI classification
- Contraindicated
- Selexipag Class
- Prostacyclin Receptor Agonist
- Gemfibrozil Class
- Peroxisome Proliferator Receptor alpha Agonist
- Management
- Confirm exact products with your pharmacist
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP2C8 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Selexipag and your doctor is considering prescribing Gemfibrozil (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider